



Why and when COPD patients should be evaluated (screened) and treated for expiratory flow limitation (EFL)

Author: Dr Michael Polkey MD, PhD, Consultant chest physician, Royal Brompton & Harefield Hospital, London, UK

Summary

Expiratory flow limitation (EFL) is a feature of Chronic Obstructive Pulmonary Disease (COPD), which can lead to air trapping and breathlessness. In noninvasive ventilation (NIV) users, EFL is best overcome by titrating the level of applied EPAP to overcome EFL, thus relieving air trapping. EFL can be worsened through the night by the effects of posture and, over the medium term, by disease progression or intercurrent inflammation or exacerbation. Next-generation ventilators can measure EFL on a breath-by-breath basis and titrate EPAP to overcome EFL.

Introduction

EFL is the cardinal physiological abnormality in COPD¹ and occurs when the pressure outside the airway exceeds the recoil forces holding the airway open (Figure 1).

Intrinsic pathophysiological processes of inflammation may make this more likely by narrowing airways. Loss of recoil force occurs in COPD because lung destruction (i.e. emphysema) weakens the structures holding the airway open. The point of collapse is termed the choke point (Figure 2).

Although other techniques are available in a research environment (example: negative expiratory pressure), the most clinically practical way of identifying EFL is using FOT.² By using the forced oscillation technique (FOT), flow limitation can be measured noninvasively by comparing the difference between inspiratory and expiratory reactance; the underlying principle is that, when the airway is closed, reactance changes dramatically because FOT is then only assessing the airway up to the choke point rather than the entire respiratory system.²




Figure 1




Figure 2

When should you suspect EFL?

In patients with COPD, as might be expected from physiology, EFL is more prevalent in those with more severe disease and those with more extensive emphysema. EFL leads to air trapping whenever minute ventilation is increased, and this has often been studied during exercise and is termed dynamic hyperinflation (Figure 3).




Figure 3

Dynamic hyperinflation is associated with breathlessness in COPD because the increased neural drive is required due to the respiratory system operating closer to total lung capacity where the pressure-volume curve is flatter. This is because the inspiratory muscles are operating at a mechanical disadvantage. Air trapping during sleep may manifest as a sense of hyperinflation, breathlessness or concern of difficulty breathing out. EFL assessment using FOT is more flexible than spirometry since it can evaluate airway obstruction continuously and is, therefore, suitable for use during exercise and sleep.

Clinically the likelihood of EFL being present in an upright patient are increased in those with an FEV₁ less than 50%, mMRC (modified Medical Research Scale) dyspnoea score ≥ 2 and IC/TLC ratio < 0.5 . Evidence suggests that patients with EFL are most likely to benefit from interventions, which reduce static or dynamic lung volumes. These are bronchodilators, gases that reduce minute ventilation (e.g. high-flow oxygen, or low-density gases) or patient alterations in their breathing pattern. Although data does not currently exist, such interventions might also include lung volume reduction (whether surgical or bronchoscopic) and the use of ambulatory EPAP.

EFL, BMI and posture

In COPD patients, flow limitation is independently associated with increasing body mass index.³ EFL is also observed in patients with obesity alone, although the effect is most marked when BMI exceeds 50 kg/m². EFL is worse when in the supine position because, since the effect of gravity of abolishing FRC is lower, it in turn reduces expiratory flow rates. Studies in both obese patients and patients with COPD suggest the prevalence of EFL increases while in the supine position.^{4,5} More data is required to understand the prevalence and or impact of home NIV users (FEV₁ $< 50\%$) where their flow limitation increases when in the supine position.

EFL and disease progression

Acute exacerbation of COPD leads to airway inflammation, which increases airway resistance and thus makes EFL more prevalent. This would lead to a requirement for increased EPAP in ventilator users and, in principle, could be used as a way of detecting exacerbation (Figure 4). However, this proposition would need to be tested in practice since observational data suggests substantial day-to-day variation³ and, in fact, a home monitoring program, which included home FOT measurement, was not shown to be beneficial in a study of non-ventilator users.⁶ Since COPD, due to progressive emphysema, worsens with time, the prevalence tends to increase in a COPD cohort over time. In addition, it is well established that some patients have a frequent exacerbator phenotype and one might expect these to have a wider variation in measures of EFL.



Detecting and Abolishing Expiratory Flow Limitation in Hypercapnic COPD Patients




Figure 4


EFL and the COPD patient who uses NIV

A number of circumstances could conceptually change the prevalence or severity of EFL in a COPD patient who uses a ventilator at night. First, data noted above suggest that the likelihood of EFL increases when supine. Second, medicines used for treating bronchoconstriction could wear off during the night. Third, movement of phlegm could change airway dynamics and, fourth, in the presence of co-existent fluid retention, cranial fluid shift might change airway dynamics. Thus a device, like the BiPAP A40 EFL NIV, which can adjust EPAP to differing levels of EFL, may have advantages, although this will need to be confirmed in clinical trials.

Why and when to evaluate COPD patients for EFL

EFL is seldom evaluated in practice although its downstream consequences, such as dynamic hyperinflation, sometimes are. Clinicians tend to be outcome-driven. Therefore, potential indications for investigating the presence of EFL might include:

1. Intolerance of CPAP or NIV where posture-related EFL is suspected to be the cause of the clinician's inability to detect optimal EPAP. FOT can be incorporated into ventilator design and detect EFL.⁴ If the ventilator then adjusts EPAP to match the intrinsic PEEP which arises as a result of the EFL, the work of breathing is reduced
2. Disease variation; patients with rapidly progressive disease or those with frequent variation due to exacerbation may develop episodic EFL
3. Where it is desired to use ambulatory pressure support (or CPAP in the case of Excessive Dynamic Airway Collapse (EDAC)) to improve exercise performance or as an adjunct to pulmonary rehabilitation
4. In the selection of patients for lung volume reduction interventions



Studies related to EFL in COPD

X5 Reactance measured with FOT and COPD

Reference	Technique	Number studied	Main findings
Crim 2011 ⁷	FOT	N=2054	Progressive increase in X5 with GOLD stage, reduced with bronchodilators. Poor relationship with CT extent of emphysema.

EFL and COPD severity

Reference	Technique	Number studied	EFL upright	EFL supine	Main findings
Mikamo 2014 ⁸	FOT	74	37/74	Not done	FL relates Emphysema score, MEF ₂₅₋₇₅ , FRC and whole breath X5. ¹
Aarli 2015 ³	FOT	425	78/4259	Not done	FL per se not analysed but ΔXrs greater with falling FEV ₁ , IC, 6MW and rising SGRQ, RV and BMI
Dean 2017 ¹⁰	FOT	147	55/147	Not done	EFL current smokers, lower FEV ₁ , higher RV, FRC, higher SGRQ, symptom scores, lower 6MW Note: of those followed up at 2 years 6/20 did not retain FL
Aarli 2017 ⁹	FOT	425	78/425	Not done	EFL patients had greatest drop in 6MW, more exacerbations (1.6 yr vs 0.7 if NFL), shorter time to AECOPD
Timmins 2012 ¹¹	FOT	26	Not stated	Not done	EFL index related to CT emphysema and FEV ₁
Vargas 2009 ¹²	NEP	35	25/35	Not done	Patients had been recently extubated
Boni 2002 ¹³	NEP	20	11/35	Not done	No differences (small sample size)

EFL and intervention in COPD (Posture)

Reference	Technique	Number studied	FEV ₁ (% pred)	EFL upright	EFL supine	Main findings
Baydur 2004 ¹⁴	NEP	21	39	4/721	3/21	No change with posture in other conditions
Chiari 2014 ⁵	FOT	40		13/40	27/40	FEV ₁ , FEV ₁ /FVC ratio, MEF ₂₅₋₇₅ related to EFL upright and DLCO, KCO, mMRC related to EFL supine
Dellaca 2009 ⁴	FOT	7	38	43% breaths	78% breaths	Analysed by breath

EFL and intervention in COPD (Exercise)

Reference	Technique	Number studied	Mean FEV ₁ (% pred)	Intervention	Main findings
Theodorakopoulou 2017 ¹⁵	NEP	42 (16 FL, 26 NFL)	50	PR	6 FL at rest and exercise 26 NFL at rest and exercise 10 FL only during exercise

¹Whole breath X5 is known to relate to FEV₁

EFL and intervention in COPD (Other)

Reference	Technique	Number studied (patients/controls)	Mean FEV ₁ (% pred)	Intervention	Main findings
Chen 2014 ¹⁶	NEP	15/13	41	Endurance exercise	No change
Vargas 2009 ¹²	NEP	25/none	?	Intrapulmonary percussive ventilation (IPV)	Magnitude of EFL reduced in 24 of 25. 3/25 no longer EFL
Ogino 2015 ¹⁷	FV loop superimp.	16/16	51	Arm bracing	Substantial reduction in COPD patients, no EFL in controls
Theodorakopoulou 2017 ¹⁵	NEP	42 (16 FL, 26 NFL)	50	PR	After rehabilitation only 1/16 FL and then only at peak exercise. Improvement related to breathing pattern change
Dellaca 2009 ¹⁸	FOT	42, no control	42	Salbutamol 5mg neb	8 of 20 were not FL after salbutamol
Alvisi 2003 ¹⁹	?	10 (8 FL, 2 NFL)	?	Oxygen 30%	2/8 no longer FL
Boni 2002 ¹³	NET	11 FL, 9 NFL	44	Salbutamol 400µg	Reduced dyspnea and increased IC but no effect in NFL patients
Tantucci 1998 ²⁰	NET	11 FL, 7 NFL	54 NFL, 40 FL	Salbutamol 400µg	No FL patient changed status but only this subgroup increased IC
D'Angelo 2009 ²¹	NET	13 FL, 13 NFL	49 FL, 64 NFL	Heliox	No clear benefit to Heliox in FL patients but small study

Obesity and EFL

Reference	BMI (kg/m ²)	Technique	Main finding
Spyratos 2007 ²²	n/a ²	NEP	14/21 FL before thoracocentesis, 7/21 afterwards
Baydur 2004 ¹⁴	42	NEP	No EFL in 9/9
Ferretti 2001 ²³	51	NEP	EFL 10/46 upright, 27/46 supine
Pankow 1998 ²⁴	44	NEP	EFL 2/8 upright, 7/8 supine

EFL during exacerbation

Reference	Tests	Patients/controls	Mean FEV ₁ (% pred)	Scenario	Main finding
Jetmanali 2015 ²⁵	FOT	29/not studied	31	Recovery AECOPD	Fell during admission in those with FL, no change in those without EFL

²Spyratos studied pleural effusion which may be considered a localised form of obesity in this context

References

1. Potter WA, Olafsson S, Hyatt RE. Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. *J Clin Invest*. 1971;50:910-919.
2. Dellaca RL, Santus P, Aliverti A, et al. Detection of expiratory flow limitation in COPD using the forced oscillation technique. *The European respiratory journal*. Feb 2004;23(2):232-240.
3. Aarli BB, Calverley PM, Jensen RL, Eagan TM, Bakke PS, Hardie JA. Variability of within-breath reactance in COPD patients and its association with dyspnoea. *The European respiratory journal*. Mar 2015;45(3):625-634.
4. Dellaca RL, Rotger M, Aliverti A, Navajas D, Pedotti A, Farre R. Noninvasive detection of expiratory flow limitation in COPD patients during nasal CPAP. *Eur Respir J*. May 2006;27(5):983-991.
5. Chiari S, Bassini S, Braghini A, Corda L, Boni E, Tantucci C. Tidal expiratory flow limitation at rest as a functional marker of pulmonary emphysema in moderate-to-severe COPD. *COPD*. Feb 2014;11(1):33-38.
6. Walker PP, Pompilio PP, Zanaboni P, et al. Telemonitoring in COPD: The CHROMED Study, a Randomized Clinical Trial. *American journal of respiratory and critical care medicine*. Mar 20 2018.
7. Crim C, Celli B, Edwards LD, et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. *Respiratory medicine*. Jul 2011;105(7):1069-1078.
8. Mikamo M, Shirai T, Mori K, et al. Predictors of expiratory flow limitation measured by forced oscillation technique in COPD. *BMC pulmonary medicine*. Feb 19 2014;14:23.
9. Aarli BB, Calverley PM, Jensen RL, et al. The association of tidal EFL with exercise performance, exacerbations, and death in COPD. *International journal of chronic obstructive pulmonary disease*. 2017;12:2179-2188.
10. Dean J, Kolsum U, Hitchen P, Gupta V, Singh D. Clinical characteristics of COPD patients with tidal expiratory flow limitation. *International journal of chronic obstructive pulmonary disease*. 2017;12:1503-1506.
11. Timmins SC, Diba C, Farrow CE, et al. The relationship between airflow obstruction, emphysema extent, and small airways function in COPD. *Chest*. Aug 2012;142(2):312-319.
12. Vargas F, Boyer A, Bui HN, Guenard H, Gruson D, Hilbert G. Effect of intrapulmonary percussive ventilation on expiratory flow limitation in chronic obstructive pulmonary disease patients. *Journal of critical care*. Jun 2009;24(2):212-219.
13. Boni E, Corda L, Franchini D, et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. *Thorax*. Jun 2002;57(6):528-532.
14. Baydur A, Wilkinson L, Mehdian R, Bains B, Milic-Emili J. Extrathoracic expiratory flow limitation in obesity and obstructive and restrictive disorders: effects of increasing negative expiratory pressure. *Chest*. Jan 2004;125(1):98-105.
15. Theodorakopoulou EP, Gennimata SA, Harikiopoulou M, et al. Effect of pulmonary rehabilitation on tidal expiratory flow limitation at rest and during exercise in COPD patients. *Respiratory physiology & neurobiology*. Apr 2017;238:47-54.
16. Chen R, Chen R, Chen X, Chen L. Effect of endurance training on expiratory flow limitation and dynamic hyperinflation in patients with stable chronic obstructive pulmonary disease. *Internal medicine journal*. Aug 2014;44(8):791-800.
17. Ogino T, Mase K, Nozoe M, et al. Effects of Arm Bracing on Expiratory Flow Limitation and Lung Volume in Elderly COPD Subjects. *Respiratory care*. Sep 2015;60(9):1282-1287.
18. Dellaca RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. *The European respiratory journal*. Jun 2009;33(6):1329-1337.
19. Alvisi V, Mirkovic T, Nesme P, Guerin C, Milic-Emili J. Acute effects of hyperoxia on dyspnea in hypoxemia patients with chronic airway obstruction at rest. *Chest*. Apr 2003;123(4):1038-1046.
20. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. *The European respiratory journal*. Oct 1998;12(4):799-804.
21. D'Angelo E, Santus P, Civitillo MF, Centanni S, Pecchiari M. Expiratory flow-limitation and heliox breathing in resting and exercising COPD patients. *Respiratory physiology & neurobiology*. Dec 31 2009;169(3): 291-296.
22. Spyrtos D, Sichletidis L, Manika K, Kontakiotis T, Chloros D, Patakas D. Expiratory flow limitation in patients with pleural effusion. *Respiration; international review of thoracic diseases*. 2007;74(5):572-578.
23. Ferretti A, Giampiccolo P, Cavalli A, Milic-Emili J, Tantucci C. Expiratory flow limitation and orthopnea in massively obese subjects. *Chest*. May 2001;119(5): 1401-1408.
24. Pankow W, Podszus T, Gutheil T, Penzel T, Peter J, Von Wichert P. Expiratory flow limitation and intrinsic positive end-expiratory pressure in obesity. *Journal of applied physiology*. Oct 1998;85(4):1236-1243.
25. Jetmalani K, Timmins S, Brown NJ, et al. Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission. *International journal of chronic obstructive pulmonary disease*. 2015;10:939-945.

